Hemab Therapeutics’ (NASDAQ:COAG – Get Free Report) lock-up period will expire on Wednesday, October 28th. Hemab Therapeutics had issued 16,750,000 shares in its IPO on May 1st. The total size of the offering was $301,500,000 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on COAG. Rodman & Renshaw began coverage on Hemab Therapeutics in a research report on Monday, October 12th. They issued a “buy” rating and a $56.00 price target for the company. Weiss Ratings downgraded Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. Wedbush boosted their price objective on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. HC Wainwright upped their price objective on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Jefferies Financial Group raised their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.71.
Check Out Our Latest Report on Hemab Therapeutics
Hemab Therapeutics Trading Down 1.2%
NASDAQ:COAG opened at $34.40 on Friday. Hemab Therapeutics has a fifty-two week low of $23.00 and a fifty-two week high of $55.42. The firm’s 50-day simple moving average is $39.01. The stock has a market cap of $1.61 billion and a PE ratio of -1.39.
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). Sell-side analysts forecast that Hemab Therapeutics will post -3.10 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new stake in Hemab Therapeutics in the 2nd quarter worth approximately $19,226,000. Braidwell LP purchased a new position in shares of Hemab Therapeutics during the 2nd quarter valued at $5,877,000. State Street Corp purchased a new position in shares of Hemab Therapeutics during the 2nd quarter valued at $2,825,000. Opaleye Management Inc. purchased a new position in shares of Hemab Therapeutics during the 2nd quarter valued at $1,750,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Hemab Therapeutics in the second quarter worth $688,000.
About Hemab Therapeutics
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious bleeding disorders. The company’s research is aimed at addressing conditions in which patients experience inadequate clot formation or difficulty controlling bleeding, including rare inherited and acquired disorders.
Hemab’s lead investigational program, HMB-001, is being developed as a potential treatment for Glanzmann thrombasthenia, a rare inherited platelet disorder that can cause severe and recurring bleeding.
Featured Stories
- Five stocks we like better than Hemab Therapeutics
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
